Evidence map›Paper›PMID 41033998›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Tumor Inflammation-associated Neurotoxicity Following CD19-targeted Chimeric Antigen Receptor T-cell Therapy in a Patient with High-grade B-cell Lymphoma.

Kenjiro Hino, Taro Edahiro, Tsuyoshi Muta, Hiroshi Ureshino, Suzuka Nakatani, Takuya Nunomura, Takeshi Okatani, Nao Yoshida, Ren Chishaki, Tetsumi Yoshida and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kenjiro HinoDepartment of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan.
Taro EdahiroDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Tsuyoshi MutaDepartment of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan.
Hiroshi UreshinoDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Suzuka NakataniDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Takuya NunomuraDepartment of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan.
Takeshi OkataniDepartment of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan.
Nao YoshidaDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Ren ChishakiDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Tetsumi YoshidaDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Takero ShindoDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 41-year-old man with high-grade B-cell lymphoma developed neurolymphomatosis (NL) after frontline chemotherapy. He received CD19 chimeric antigen receptor (CAR) T-cell therapy (lisocabtagene maraleucel) and subsequently developed tumor inflammation-associated neurotoxicity (TIAN) type 2, a localized neurological event distinct from immune effector cell-associated neurotoxicity syndrome. Conservative treatment resulted in a neurological recovery and complete remission. This case suggests that CD19 CAR T-cell therapy may be effective for NL, and it highlights the importance of recognizing TIAN in patients with central nervous system involvement. As CAR T-cell use has increased in Japan, awareness of such complications is crucial for performing safe and effective treatment.

Indexed as

Antigens, CD19Immunotherapy, AdoptiveLymphoma, B-CellNeurotoxicity SyndromesReceptors, Chimeric AntigenAdultHumansMaleAntigens, CD19Receptors, Chimeric Antigenchimeric antigen receptor T-cell therapyhigh-grade B-cell lymphomaneurolymphomatosistumor inflammation-associated neurotoxicity

Identifiers

PMID41033998
PMCPMC13222697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.